Kanzatec LLC, is representing Geneasys exclusively, to divest all the KeyLab patent applications and technology assets. The KeyLab portfolio, which may provide a strategic advantage to one of your clients represents a "Lab on a Chip"—a low cost DNA based diagnostic device (USB), that can be used anywhere, by anybody, using a smart phone, tablet or laptop. Geneasys has a portfolio of 350+ US patent applications (plus PCT coverage), covering KeyLab, including alternative approaches and ring-fencing the core technology. 17 applications have been allowed already by the USPTO, with the remainder pending The portfolio has priority dates of 2010 and provides the buyer with a broad set of applications that can be strategically prosecuted to attain excellent future patent protection.

1. For more info contact Fas Mosleh (650 468 0401) – FMosleh@Kanzatec.com ©Kanzatec LLC, July 2013
Disclaimer: This report contains no legal opinion and is purely technical in nature. Therefore, no content of this report should be construed as having any legal weight or
being legally dispositive in any manner. The report should not be used for any litigation or dispute related to patent, product or process.
Geneasys KeyLab™ System for Molecular Diagnostics
Sale of Patent Portfolio and Related IP Assets
What is it?
• Lab on a chip, low cost DNA based diagnostic device (USB), that can be used anywhere, by anybody using a
cellphone or laptop
• Can detect up to 48 DNA/RNA markers of infectious or hereditary diseases simultaneously
• Process : Plug into USB port, insert swab and process/display results
What are we selling?
Geneasys has a portfolio of 350+ US patent applications (plus PCT coverage), covering KeyLab, including alternative
approaches and ring-fencing the core technology. 17 applications have been allowed already by the USPTO, with the
remainder pending :

2. For more info contact Fas Mosleh (650 468 0401) – FMosleh@Kanzatec.com ©Kanzatec LLC, July 2013
Disclaimer: This report contains no legal opinion and is purely technical in nature. Therefore, no content of this report should be construed as having any legal weight or
being legally dispositive in any manner. The report should not be used for any litigation or dispute related to patent, product or process.
• Estimated current global market size for Point
of Care (human) diagnostics is
$14 bn per annum
• Molecular Diagnostics (MDx) market currently
$5Bn with CAGR of > 15%
• Advances in genetics, genomics and
molecular science are driving the market
• Infectious diseases are the most
important applications, followed by cancer
and cardiovascular conditions
• Drug companion diagnostics development
is becoming a major driver
Market Opportunity
0
1000
2000
3000
4000
5000
6000
InfectiousDiseases
Blood
Screening
Genotypingand
Oncology
Pharm
acodiagnostics
Tissue
Typing
Sales 2009
Sales 2014
Molecular Diagnostics Market US$M